Patents by Inventor Austin Gurney

Austin Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20130273044
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 17, 2013
    Inventors: Austin GURNEY, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20130251705
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 8540989
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: September 24, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin Gurney
  • Methods of using antibodies that bind the glutamate ligand binding region of Notch1
    Patent number: 8460661
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 11, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
  • Nucleic acids encoding IL-17 homologous receptor-like polypeptides and therapeutic uses thereof
    Patent number: 8455217
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 4, 2013
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, William I. Wood
  • Compositions and Methods for Treating and Diagnosing Cancer
    Publication number: 20130121993
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Application
    Filed: February 29, 2012
    Publication date: May 16, 2013
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventor: AUSTIN GURNEY
  • Compositions and Methods for Treating and Diagnosing Cancer
    Publication number: 20130115206
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Application
    Filed: February 29, 2012
    Publication date: May 9, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron K. Sato
  • Antibodies to the NOTCH1 receptor
    Patent number: 8404237
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: March 26, 2013
    Assignee: OncoMed Pharamaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Wnt Antagonists and Methods of Treatment and Screening
    Publication number: 20130034551
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Application
    Filed: January 12, 2011
    Publication date: February 7, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Sanjeev SATYAL, Satyajit MITRA, Austin GURNEY
  • ANTIBODIES TO THE NOTCH1 RECEPTOR
    Publication number: 20130030155
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: May 15, 2012
    Publication date: January 31, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof
    Patent number: 8338132
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Audrey Goddard, Paul Godowski, J. Christopher Grimaldi, Austin Gurney, Hanzhong Li, Kenneth Hillan, Sarah G. Hymowitz, Daniel Tumas, Melissa A. Starovasnik, Menno VanLookeren, Richard Vandlen, Colin Watanabe, P. Mickey Williams, William I. Wood, Daniel Yansura
  • Methods of Using Antibodies That Bind The Glutamate Ligand Binding Region of Notch1
    Publication number: 20120308558
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 30, 2011
    Publication date: December 6, 2012
    Inventors: Austin GURNEY, Aaron SATO, Maureen FITCH-BRUHNS
  • Nucleic acid molecules encoding soluble frizzled (FZD) receptors
    Patent number: 8324361
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: December 4, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2
    Patent number: 8206713
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 26, 2012
    Assignee: Oncomed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20120128627
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Application
    Filed: December 8, 2011
    Publication date: May 24, 2012
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 8158758
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 17, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin Gurney
  • RTD RECEPTOR
    Publication number: 20120042400
    Abstract: Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided.
    Type: Application
    Filed: November 29, 2010
    Publication date: February 16, 2012
    Applicant: GENENTECH, INC.
    Inventors: Avi J. Ashkenazi, Austin Gurney
  • Antibodies that bind the glutamate ligand binding region of Notch1
    Patent number: 8088617
    Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: January 3, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
  • Methods of treatment using antibodies to IL-17 homologous polypeptides
    Patent number: 8075888
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: December 13, 2011
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20110195065
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: January 20, 2011
    Publication date: August 11, 2011
    Inventors: John A. LEWICKI, Austin GURNEY, Timothy HOEY, Wan-Ching YEN, Sanjeev SATYAL